Dotinurad Solid Formulation for Stability and Clean Tableting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of Dotinurad-containing pharmaceutical preparations lack stability and productivity, as exemplified by JP 5325065B2, which does not provide a suitable formulation for a solid pharmaceutical preparation with Dotinurad as the active component.
Innovation Solution
A solid pharmaceutical preparation containing Dotinurad or a pharmacologically acceptable salt thereof, incorporating specific amounts of sugar alcohol, cellulose derivative, lactose hydrate, disintegrant, binding agent, and lubricant, such as D-mannitol, crystalline cellulose, lactose hydrate, carmellose, hypromellose, and magnesium stearate, to enhance stability and productivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional excipients (lactose, corn starch, hydroxypropylcellulose, magnesium stearate) are used in Dotinurad formulation, then the pharmaceutical preparation can be manufactured, but the stability of Dotinurad deteriorates during long term storage
Solution Approach 1:
The patent changes the chemical parameters of the excipients by selecting specific sugar alcohols (mannitol, xylitol, sorbitol) and cellulose derivatives with defined characteristics. This parameter change resolves the stability issue by selecting excipients that do not promote Dotinurad decomposition during long term storage
Solution Approach 2:
The patent creates a composite formulation system combining Dotinurad with specific ratios of sugar alcohol (10-50 wt%) and cellulose derivative (5-30 wt%). This composite approach resolves the contradiction by forming a stable pharmaceutical composition that maintains Dotinurad integrity over extended storage periods
2Reliability
If formulation components are optimized for stability, then Dotinurad stability improves, but manufacturing complexity increases
Solution Approach 1:
The patent establishes specific parameter ranges for excipient content (sugar alcohol: 10-50 wt%, cellulose derivative: 5-30 wt%) that simultaneously achieve stability and manufacturability. These defined parameters simplify the formulation development process while ensuring stable products
Solution Approach 2:
The patent selects commonly available, inexpensive excipients (sugar alcohols and cellulose derivatives) that are easy to source and handle. This approach reduces formulation complexity and manufacturing costs while maintaining stability
Data Source
AI summary
The purpose of the present invention is to provide a solid pharmaceutical preparation of excellent stability and producibility, the preparation including, as an active ingredient, 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole. This solid pharmaceutical preparation contains 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole or a pharmaceutically acceptable salt thereof and a sugar alcohol and/or a cellulose derivative.